文献速递前列腺癌

寡复发淋巴结转移性前列腺癌的转移灶导向治疗:立体定向体部放疗与选择性淋巴结放疗的疗效及毒性多中心分析

Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
PubMed 文献 · Eur Urol · 2019-07-20

多中心回顾性分析506例激素敏感性淋巴结寡复发前列腺癌患者(SBRT 309例,ENRT 197例),比较两种转移灶导向治疗的疗效与毒性。ENRT较SBRT减少淋巴结复发,但晚期毒性更高(16% vs 5%,p<0.01);单个淋巴结复发者ENRT后无转移生存更优(HR 0.50,95%CI 0.30-0.85,p=0.009)。作者假设ENRT应优先于SBRT,需随机试验验证。

要点

  • ENRT较SBRT减少淋巴结复发(p<0.001),但晚期毒性更高(16% vs 5%,p<0.01)。
  • 单淋巴结复发者ENRT后无转移生存更优(HR 0.50,95%CI 0.30-0.85,p=0.009)。
  • 作者假设ENRT应优先于SBRT治疗淋巴结寡复发,需随机试验验证。

核心结论

  • ENRT较SBRT减少淋巴结复发数量,但毒性更高。
  • 作者假设ENRT应优先于SBRT用于淋巴结寡复发治疗,该假设需随机试验评估。

研究设计与样本

  • 多中心回顾性分析,纳入506例激素敏感性淋巴结寡复发前列腺癌患者(SBRT 309例,ENRT 197例),淋巴结≤5个(N1/M1a),治疗于2004年至2017年,中位随访36个月(四分位距23-56)。
  • SBRT定义为每病灶每次至少5 Gy、最多10次;ENRT定义为 elective 淋巴结至少45 Gy、最多25次,可同时对可疑淋巴结加量。
  • 放疗选择由治疗医师决定,各中心间治疗分布不平衡;淋巴结复发通过PET/CT(97%)或常规影像(3%)检测。

主要发现

  • ENRT较SBRT淋巴结复发更少(p<0.001)。
  • 多变量分析中,复发时仅1个淋巴结的患者ENRT后无转移生存更长(HR 0.50,95%CI 0.30-0.85,p=0.009)。
  • ENRT晚期毒性高于SBRT(16% vs 5%,p<0.01)。

临床怎么用

  • 原文未据此给出推荐;作者假设ENRT应优先于SBRT治疗淋巴结寡复发,该假设需随机试验评估。

局限性

  • ENRT队列激素治疗使用更多。
  • 随访未标准化。
  • 作者指出该假设需随机试验评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still lacking. OBJECTIVE: To compare outcome and toxicity between both treatments. Primary endpoint was metastasis-free survival, adjusted for selected variables (aMFS). DESIGN, SETTING, AND PARTICIPANTS: This was a multi-institutional, retrospective analysis of 506 (SBRT: 309, ENRT: 197) patients with hormone-sensitive nodal oligorecurrent PC (five or fewer lymph nodes (LNs; N1/M1a), treated between 2004 and 2017. Median follow-up was 36 mo (interquartile range 23-56). INTERVENTION: SBRT was defined as a minimum of 5 Gy per fraction to each lesion with a maximum of 10 fractions. ENRT was defined as a minimum dose of 45 Gy in up to 25 fractions to the elective nodes, with or without a simultaneous boost to the suspicious node(s). The choice of radiotherapy (RT) was at the discretion of the treating physician, with treatments being unbalanced over the centers. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In total, 506 patients from 15 different treatment centers were included. Primary treatment was radical prostatectomy, RT, or their combination. Nodal recurrences were detected by positron emission tomography/computer tomography (97%) or conventional imaging (3%). Descriptive statistics was used to summarize patient characteristics. RESULTS AND LIMITATIONS: ENRT was associated with fewer nodal recurrences compared with SBRT (p < 0.001). In a multivariable analysis, patients with one LN at recurrence had longer aMFS after ENRT (hazard ratio: 0.50, 95% confidence interval 0.30-0.85, p = 0.009). Late toxicity was higher after ENRT compared with that after SBRT (16% vs. 5%, p < 0.01). Limitations include higher use of hormone therapy in the ENRT cohort and nonstandardized follow-up. CONCLUSIONS: ENRT reduces the number of nodal recurrences as compared with SBRT, however at higher toxicity. Our findings hypothesize that ENRT should be preferred to SBRT in the treatment of nodal oligorecurrences. This hypothesis needs to be evaluated in a randomized trial. PATIENT SUMMARY: This study investigated the difference between stereotactic and elective nodal radiotherapy in treating limited nodal metastatic prostate cancer. Nodal relapse was less frequent following elective nodal radiotherapy than following stereotactic body radiotherapy, and thus elective nodal radiotherapy might be the preferred treatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. Eur Urol. 2019. PMID: 31331782. doi:10.1016/j.eururo.2019.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。